The 19th European Association for Haemophilia and Allied Disorders (EAHAD) Annual Congress, held in Dublin from 3-6 February 2026, showcased many exciting novel advancements in haemophilia care. Below, learn more about the highly anticipated late-breaking abstracts, showcasing fresh, innovative thinking that we will all want to follow closely.
First-in-class efanesoctocog alfa ‘highly efficacious’ in severe haemophilia A
Three-year data from the XTEND-ed study (NCT04644575) confirm that first-in-class once-weekly efanesoctocog alfa maintains durable bleed protection in severe haemophilia A. Following 217 patients, results showed a low overall model-based annualised bleeding rates (ABR) of 0.61. Of the 341 treated bleeds during the efficacy period (most commonly joints, muscles and skin/mucosa), 93.3% were resolved with a single 50 IU/kg dose, with 89.4% of responses rated as “excellent” or “good”. These findings reinforce its sustained efficacy for long-term prophylaxis and reliable on-demand treatment.
Mim8: Flexible paediatric prophylaxis
The phase III FRONTIER3 study (NCT05306418) evaluated Mim8 (denecimig) in 70 children aged 1–11 with haemophilia A (any severity). After 26 weeks of weekly dosing, nearly half of the participants switched to a once-monthly regimen. Both schedules provided robust protection; over 80% of patients achieved zero treated bleeds in the study’s second half, and all target joints resolved by week 52. Mim8 was well tolerated with no severe adverse or thromboembolic events, supporting its role as a flexible, low-burden option for paediatric care.
NXT007: Switching from emicizumab
Part C of the NXTAGE trial (jRCT2080224835) explored switching from emicizumab to the more potent bispecific antibody NXT007. In 14 participants, the switch was well tolerated without a washout period. Higher-dose cohorts reached non-haemophilic factor VIII-equivalent activity and normalized thrombin generation, resulting in zero treated bleeds. These preliminary results suggest NXT007 is a promising next-step therapy for patients requiring higher hemostatic protection than current bispecifics provide.
Marstacimab: Improving joint health with inhibitors
The phase III BASIS trial (NCT03938792) reported the impact of marstacimab, a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), in patients with inhibitors. In a subgroup of 48 patients previously on on-demand therapy, weekly subcutaneous marstacimab reduced the mean ABR for joint bleeds from 15.15 to 1.10. Furthermore, the ABR for target joint bleeds dropped from 6.42 to 0.79. By eliminating most target joints over 12 months, marstacimab offers a subcutaneous, non-factor alternative to prevent progressive arthropathy.
References
- 19th Annual Congress of European Association for Haemophilia and Allied Disorders 2026, February 3–6, 2026, Dublin. Haemophilia. 2026;32(S1):1-235
- Scientific Programme. Available at: https://eahadcongress.com/scientific-programme/#friday (date last accessed: 12 February 2026)
Related content
- FDA grants orphan drug status to zavabresib in myelofibrosis
- PARADIGM challenges role of intensive chemotherapy in newly diagnosed AML
- FDA grants orphan drug status to zavabresib in myelofibrosis
This content has been developed independently by Touch Medical Media for touchHAEMATOLOGY. Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.
Cite: EAHAD 2026: Discover the late-breaking abstracts. touchHAEMATOLOGY. 12th February 2026.
Editor: Sophie Nickelson, Editorial Director
Disclosures: This short article was prepared by touchHAEMATOLOGY. The content was developed and edited by human editors. No fees or funding were associated with its publication. touchHAEMATOLOGY utilize AI as an editorial tool (ChatGPT (GPT-4o) [Large language model]. https://chat.openai.com/chat).
SIGN UP to touchHAEMATOLOGY!
Join our global community today for access to thousands of peer-reviewed articles, expert insights and learn-on-the-go education across 150+ specialties, plus concise email updates and newsletters so you never miss out.
